Yousif, Mustafa http://orcid.org/0000-0002-4785-8579
van Diest, Paul J.
Laurinavicius, Arvydas
Rimm, David
van der Laak, Jeroen
Madabhushi, Anant
Schnitt, Stuart
Pantanowitz, Liron
Article History
Received: 4 May 2021
Revised: 12 September 2021
Accepted: 27 September 2021
First Online: 18 November 2021
Declarations
:
: Paul J. van Diest serves on the scientific advisory of Sectra (non-paid). Arvydas Laurinavicius is an independent scientific advisor (non-paid) to the portal ExternalRef removed, and a co-author on international patent application (no commercial interest). Anant Madabhushi is an equity holder in Elucid Bioimaging and in Inspirata Inc. In addition, Madabhushi has served as a scientific advisory board member for Inspirata Inc., Astrazeneca, Bristol Meyers-Squibb, and Merck. Currently, he serves on the advisory board of Aiforia Inc., has sponsored research agreements with Philips, AstraZeneca, Boehringer-Ingelheim, and Bristol Meyers-Squibb. Madabhushi’s technology has been licensed to Elucid Bioimaging and he is also involved in a NIH U24 grant with PathCore Inc, and 3 different R01 grants with Inspirata Inc. Liron Pantanowitz is on the scientific advisory board for Ibex and NTP and serves as a consultant for Hamamatsu. David L. Rimm has served as an advisor for Astra Zeneca, Agendia, Amgen, BMS, Cell Signaling Technology, Cepheid, Danaher, Daiichi Sankyo, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Sanofi, Ventana, and Ultivue. Amgen, Cepheid, NavigateBP, NextCure, and Konica Minolta fund research in David L. Rimm’s lab. Stuart J. Schnitt is on the scientific advisory boards of PathAI and Ibex. Jeroen van der Laak is a member of the advisory boards of Philips, The Netherlands, and ContextVision, Sweden, and received research funding from Philips, The Netherlands; ContextVision, Sweden; and Sectra, Sweden in the last five years.